SG11202102416SA - Methods for treating pancreatitis - Google Patents
Methods for treating pancreatitisInfo
- Publication number
- SG11202102416SA SG11202102416SA SG11202102416SA SG11202102416SA SG11202102416SA SG 11202102416S A SG11202102416S A SG 11202102416SA SG 11202102416S A SG11202102416S A SG 11202102416SA SG 11202102416S A SG11202102416S A SG 11202102416SA SG 11202102416S A SG11202102416S A SG 11202102416SA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- treating pancreatitis
- pancreatitis
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862729354P | 2018-09-10 | 2018-09-10 | |
| PCT/US2019/050262 WO2020055768A1 (en) | 2018-09-10 | 2019-09-09 | Methods for treating pancreatitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202102416SA true SG11202102416SA (en) | 2021-04-29 |
Family
ID=69776851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202102416SA SG11202102416SA (en) | 2018-09-10 | 2019-09-09 | Methods for treating pancreatitis |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220049011A1 (en) |
| EP (1) | EP3849605A4 (en) |
| JP (1) | JP2022500382A (en) |
| KR (1) | KR20210073515A (en) |
| CN (1) | CN113056286A (en) |
| AU (1) | AU2019337564A1 (en) |
| BR (1) | BR112021004444A2 (en) |
| CA (1) | CA3112382A1 (en) |
| CL (2) | CL2021000585A1 (en) |
| IL (1) | IL281343A (en) |
| MX (1) | MX2021002761A (en) |
| SG (1) | SG11202102416SA (en) |
| WO (1) | WO2020055768A1 (en) |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4018653A (en) | 1971-10-29 | 1977-04-19 | U.S. Packaging Corporation | Instrument for the detection of Neisseria gonorrhoeae without culture |
| US4016043A (en) | 1975-09-04 | 1977-04-05 | Akzona Incorporated | Enzymatic immunological method for the determination of antigens and antibodies |
| US4471057A (en) | 1981-06-30 | 1984-09-11 | The Wistar Institute | Detection of colorectal carcinoma |
| US4424279A (en) | 1982-08-12 | 1984-01-03 | Quidel | Rapid plunger immunoassay method and apparatus |
| US5051448A (en) | 1984-07-24 | 1991-09-24 | The Mclean Hospital Corporation | GABA esters and GABA analog esters |
| US4704355A (en) | 1985-03-27 | 1987-11-03 | New Horizons Diagnostics Corporation | Assay utilizing ATP encapsulated within liposome particles |
| JPS63159763A (en) * | 1986-12-24 | 1988-07-02 | Fujirebio Inc | Reverse passive agglutination reaction reagent |
| CA2025907A1 (en) | 1989-09-21 | 1991-03-22 | Franklin D. Collins | Method of transporting compositions across the blood brain barrier |
| US5192746A (en) | 1990-07-09 | 1993-03-09 | Tanabe Seiyaku Co., Ltd. | Cyclic cell adhesion modulation compounds |
| US5559103A (en) | 1993-07-21 | 1996-09-24 | Cytel Corporation | Bivalent sialyl X saccharides |
| US5576423A (en) | 1994-12-02 | 1996-11-19 | Schering Corporation | Antibodies to the slam protein expressed on activated T cells |
| ES2653790T3 (en) | 2005-08-05 | 2018-02-08 | Araim Pharmaceuticals, Inc. | Protective tissue peptides and uses thereof |
| FI20070853A0 (en) * | 2007-11-09 | 2007-11-09 | Glykos Finland Oy | Glycan binding monoclonal antibodies |
| KR101572286B1 (en) | 2008-01-22 | 2015-11-27 | 아라임 파마슈티칼즈, 인크. | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
| CN102137681B (en) * | 2008-08-08 | 2014-12-03 | 埃姆诺医药有限公司 | Anti-pancreatic cancer antibodies |
| SG10201809099PA (en) | 2013-07-17 | 2018-11-29 | Araim Pharmaceuticals Inc | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
| CN112695039A (en) * | 2013-08-26 | 2021-04-23 | 生物技术研发公司 | Nucleic acids encoding human antibodies against sialyl-lewis a antigens |
| MY191944A (en) | 2014-01-24 | 2022-07-20 | Ngm Biopharmaceuticals Inc | Binding proteins and methods of use thereof |
| US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
| US11326182B2 (en) * | 2016-04-29 | 2022-05-10 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
-
2019
- 2019-09-09 CA CA3112382A patent/CA3112382A1/en active Pending
- 2019-09-09 AU AU2019337564A patent/AU2019337564A1/en active Pending
- 2019-09-09 JP JP2021513309A patent/JP2022500382A/en active Pending
- 2019-09-09 WO PCT/US2019/050262 patent/WO2020055768A1/en unknown
- 2019-09-09 US US17/274,783 patent/US20220049011A1/en active Pending
- 2019-09-09 SG SG11202102416SA patent/SG11202102416SA/en unknown
- 2019-09-09 EP EP19859491.3A patent/EP3849605A4/en active Pending
- 2019-09-09 CN CN201980073543.7A patent/CN113056286A/en active Pending
- 2019-09-09 KR KR1020217008242A patent/KR20210073515A/en unknown
- 2019-09-09 MX MX2021002761A patent/MX2021002761A/en unknown
- 2019-09-09 BR BR112021004444-2A patent/BR112021004444A2/en unknown
-
2021
- 2021-03-09 CL CL2021000585A patent/CL2021000585A1/en unknown
- 2021-03-09 IL IL281343A patent/IL281343A/en unknown
-
2022
- 2022-01-13 CL CL2022000091A patent/CL2022000091A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3112382A1 (en) | 2020-03-19 |
| IL281343A (en) | 2021-04-29 |
| EP3849605A1 (en) | 2021-07-21 |
| KR20210073515A (en) | 2021-06-18 |
| CN113056286A (en) | 2021-06-29 |
| US20220049011A1 (en) | 2022-02-17 |
| JP2022500382A (en) | 2022-01-04 |
| BR112021004444A2 (en) | 2021-06-01 |
| MX2021002761A (en) | 2021-05-31 |
| AU2019337564A1 (en) | 2021-05-06 |
| WO2020055768A1 (en) | 2020-03-19 |
| CL2021000585A1 (en) | 2021-08-13 |
| CL2022000091A1 (en) | 2022-11-18 |
| EP3849605A4 (en) | 2022-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201705673B (en) | Methods for treating skin | |
| IL254760A (en) | Method for treating cancer | |
| IL256056A (en) | Ezh2 inhibitors for treating lymphoma | |
| EP3500289A4 (en) | Methods for treating tracheobronchomalacia | |
| IL278247B (en) | Mct4 inhibitors for treating disease | |
| IL257691A (en) | Method for treating cancer | |
| HK1244217A1 (en) | Methods for treating proteinopathies | |
| HK1253238A1 (en) | Gls1 inhibitors for treating disease | |
| EP3634369C0 (en) | Methods for treating chemically relaxed hair | |
| GB201709402D0 (en) | Compounds for treating t-pll | |
| IL280128A (en) | Method for treating epilepsy | |
| GB2567616B (en) | Treatment method | |
| HK1255871A1 (en) | Cerdulatinib for treating myeloma | |
| HK1251965A1 (en) | Methods for treating epilepsy | |
| HK1248135A1 (en) | Combination method for treating cancer | |
| GB2571601B (en) | Treatment method | |
| IL281792A (en) | Treatment methods | |
| SG11202001806TA (en) | Treatment method | |
| IL281839A (en) | Treatment methods | |
| ZA202006810B (en) | Process for treating hair | |
| SG10201508795XA (en) | Method for treating cancer | |
| IL271967A (en) | Methods for treating congenital hyperinsulinism | |
| IL270867A (en) | Treatment method | |
| HK1257072A1 (en) | Method for treating multiple sclerosis | |
| IL266605A (en) | Methods for treating multiple osteochondroma (mo) |